112 results on '"Nakamura, Hideki"'
Search Results
2. Comparison of salivary gland MRI and ultrasonography findings among patients with Sjögren's syndrome over a wide age range.
- Author
-
Takagi, Yukinori, Sasaki, Miho, Eida, Sato, Katayama, Ikuo, Hashimoto, Kunio, Nakamura, Hideki, Shimizu, Toshimasa, Morimoto, Shimpei, Kawakami, Atsushi, and Sumi, Misa
- Subjects
SALIVA ,MAGNETIC resonance imaging ,SEVERITY of illness index ,SALIVARY glands ,SJOGREN'S syndrome ,PAROTID glands - Abstract
Objectives This retrospective study compared MRI and US findings among patients with SS over a wide age range. Methods Ninety patients with SS aged 8–84 years who had undergone both MRI and US examinations were divided into four groups according to age, as follows: <18 years (juvenile SS, JSS), 9 patients; 18–39 years, 12 patients; 40–69 years, 53 patients; >69 years, 16 patients. Imaging findings of parotid glands (PGs) and submandibular glands (SMGs) were compared among the four groups. Furthermore, the relationships within and between imaging findings and various clinical findings were examined. Results On MRI, patients with JSS commonly exhibited multiple high-intensity spots in the PGs on MR sialography and fat-suppressed T2-weighted imaging. With increasing SS group age, the frequencies and numbers of the high-intensity spots were lower. Fat areas on MRI and hyperechoic bands on US were rarely observed in the PGs and SMGs of patients with JSS, whereas they were more common in patients with adult SS. In addition, the presence of hyperechoic bands on US, the presence of fat areas on MRI, and decreased salivary flow were associated with one another. Conclusion Salivary gland imaging findings in patients with JSS were characterized by punctate sialectasis, whereas those findings in patients with adult SS were characterized by fatty degeneration. Distinct findings in patients with JSS and adult SS are likely to reflect differences in glandular lesion stage. MRI and US are presumably useful for evaluation of glandular lesion severity during follow-up. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
3. Intravenous cyclophosphamide treatment for systemic lupus erythematosus with severe autonomic disorders confirmed by head-up tilt table test: A case series.
- Author
-
Umeda, Masataka, Kawano, Hiroaki, Endo, Yushiro, Takatani, Ayuko, Koga, Tomohiro, Ichinose, Kunihiro, Nakamura, Hideki, Mukaino, Akihiro, Higuchi, Osamu, Nakane, Shunya, Maeda, Takahiro, and Kawakami, Atsushi
- Subjects
SYSTEMIC lupus erythematosus ,ORTHOSTATIC intolerance ,RETENTION of urine ,TILT-table test ,SINGLE-photon emission computed tomography ,POSTURAL orthostatic tachycardia syndrome ,MEDICAL sciences - Published
- 2022
- Full Text
- View/download PDF
4. Life prognosis and renal relapse after induction therapy in Japanese patients with proliferative and pure membranous lupus nephritis.
- Author
-
Okamoto, Momoko, Kitamura, Mineaki, Sato, Shuntaro, Fujikawa, Keita, Horai, Yoshiro, Matsuoka, Naoki, Tsuboi, Masahiko, Nonaka, Fumiaki, Shimizu, Toshimasa, Koga, Tomohiro, Kawashiri, Shin-ya, Iwamoto, Naoki, Tamai, Mami, Nakamura, Hideki, Origuchi, Tomoki, Nishino, Tomoya, Kawakami, Atsushi, and Ichinose, Kunihiro
- Subjects
LUPUS nephritis ,BIOPSY ,KIDNEYS ,MULTIVARIATE analysis ,RETROSPECTIVE studies ,COMMUNITY health services ,DISEASE relapse ,TREATMENT effectiveness ,COMPARATIVE studies ,SEVERITY of illness index ,DESCRIPTIVE statistics ,SURVIVAL analysis (Biometry) ,KAPLAN-Meier estimator - Abstract
Objective We aimed to compare life prognosis and renal relapse after induction therapy in proliferative (PLN) and pure membranous LN (MLN). Methods We retrospectively analysed the cases of 140 of 172 patients with LN who underwent a renal biopsy at our hospital or community hospitals from 1993 to 2016. We determined the complete response (CR) rate at 12 months after the patients had started induction therapy, and we evaluated the predictive factors for CR, life prognosis and renal relapse in PLN and pure MLN. We defined PLN as International Society of Neurology and the Renal Pathology Society (ISN/RPS) Class III or IV and MLN as ISN/RPS Class V. Results The renal pathology of 99 (70.7%) patients was classified as PLN, and that of the other 41 (29.3%) patients as MLN. Fifty patients (50.5%) with PLN and 22 patients (53.7%) with MLN achieved a CR at 12 months. A multivariate analysis showed that a lower index of chronicity in PLN and a higher total haemolytic complement (CH50) level in MLN were predictive factors for achieving a CR at 12 months. A Kaplan–Meier analysis showed that the life prognosis (P = 0.93) and renal relapse (P = 0.52) were not significantly different between PLN and MLN. Conclusions The predictive factors for a CR at 12 months post-induction therapy were index of chronicity in PLN and CH50 level in MLN. There were no significant differences in life prognosis or renal relapse between PLN and MLN in the achievement of a CR at 12 months post-induction therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
5. Harnessing biomolecular condensates in living cells.
- Author
-
Nakamura, Hideki, DeRose, Robert, and Inoue, Takanari
- Subjects
- *
NUCLEIC acids , *MOLECULAR biology , *CELL physiology , *CELLS , *DROPLETS - Abstract
As part of the 'Central Dogma' of molecular biology, the function of proteins and nucleic acids within a cell is determined by their primary sequence. Recent work, however, has shown that within living cells the role of many proteins and RNA molecules can be influenced by the physical state in which the molecule is found. Within living cells, both protein and RNA molecules are observed to condense into non-membrane-bound yet distinct structures such as liquid droplets, hydrogels and insoluble aggregates. These unique intracellular organizations, collectively termed biomolecular condensates, have been found to be vital in both normal and pathological conditions. Here, we review the latest studies that have developed molecular tools attempting to recreate artificial biomolecular condensates in living cells. We will describe their design principles, implementation and unique characteristics, along with limitations. We will also introduce how these tools can be used to probe and perturb normal and pathological cell functions, which will then be complemented with discussions of remaining areas for technological advance under this exciting theme. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
6. Development of adult T-cell leukaemia/lymphoma during the treatment of rheumatoid arthritis.
- Author
-
Okamoto, Momoko, Eguchi, Katsumi, Hida, Ayumi, Terada, Kaoru, Aramaki, Toshiyuki, Nonaka, Fumiaki, Taniguchi, Hiroaki, Moriuchi, Yukiyoshi, Nakamura, Hideki, Kawakami, Atsushi, and Ueki, Yukitaka
- Subjects
LYMPHOMAS ,RHEUMATOID arthritis treatment ,GLUCOCORTICOIDS ,TOCILIZUMAB ,ABATACEPT - Abstract
Two patients with rheumatoid arthritis (RA) developed adult T-cell leukaemia/lymphoma (ATLL) in the course of RA treatment. We previously reported another case of ATLL that developed during RA treatment and summarised all three cases of ATLL. The mean age at onset of ATLL was 63.7 ± 9.6 years and treatment regimens included biological disease-modifying anti-rheumatic drugs (bDMARDs), such as abatacept (ABT) and tocilizumab, and conventional synthetic DMARDs (i.e. iguratimod (IGU) and methotrexate [MTX]) and/or glucocorticoids. Two patients were complicated with bronchiectasis and/or interstitial pneumonia and one patient developed ATLL after MTX-related lymphoproliferative disease. All three patients with ATLL were encountered for 5 years of clinical practice at our centre. The prevalence of ATLL that developed from 78 human T-cell leukaemia virus type 1 (HTLV)-1-seropositive RA patients was 3.85%. In conclusion, we described three cases of ATLL development during the treatment for RA. It is suggested that HTLV-1 seropositive RA patients should be managed and treated carefully. A nationwide survey is necessary to elucidate if the progression to ATLL after immunosuppressive treatment for RA occurs at higher in incidence than that in the natural course of an HTLV-1 infection. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
7. Comorbid case of IgG4-related disease and primary Sjögren's syndrome.
- Author
-
Nakashima, Yoshikazu, Nakamura, Hideki, Horai, Yoshiro, Hayashi, Tomayoshi, Takagi, Yukinori, Nakamura, Takashi, and Kawakami, Atsushi
- Subjects
- *
COMORBIDITY , *SJOGREN'S syndrome , *SUBMANDIBULAR gland , *BIOPSY , *SALIVARY glands - Abstract
A 63-year-old man with enlargement of the bilateral submandibular glands visited with elevated serum IgG4. A biopsy specimen showed plasma cell infiltration with more than 50% IgG4/IgG staining, suggesting the existence of IgG4-related disease (IgG4-RD). Positive anti-SS-A/Ro antibody and the labial salivary gland's biopsy suggested existence of primary Sjögren's syndrome (pSS). Administration of glucocorticoid improved the serum IgG4 level while reducing the submandibular gland lesions. Positive TUNEL staining suggested the coexistence of IgG4-RD and pSS. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
8. Efficacy and safety of abatacept for patients with Sjögren's syndrome associated with rheumatoid arthritis: Rheumatoid Arthritis with Orencia Trial toward Sjögren's syndrome Endocrinopathy (ROSE) trial-an open-label, one-year, prospective study-Interim analysis of 32 patients for 24 weeks
- Author
-
Tsuboi, Hiroto, Matsumoto, Isao, Hagiwara, Shinya, Hirota, Tomoya, Takahashi, Hiroyuki, Ebe, Hiroshi, Yokosawa, Masahiro, Hagiya, Chihiro, Asashima, Hiromitsu, Takai, Chinatsu, Miki, Haruka, Umeda, Naoto, Kondo, Yuya, Ogishima, Hiroshi, Suzuki, Takeshi, Hirata, Shintaro, Saito, Kazuyoshi, Tanaka, Yoshiya, Horai, Yoshiro, and Nakamura, Hideki
- Subjects
ABATACEPT ,SJOGREN'S syndrome ,RHEUMATOID arthritis ,DRUG efficacy ,MEDICATION safety ,PATIENTS ,THERAPEUTICS - Abstract
Objective. To assess the efficacy and safety of abatacept for secondary Sjögren's syndrome (SS) associated with rheumatoid arthritis (RA). Methods. The primary endpoint of this 1-year, open-labeled, prospective, observational multicenter study of RA-associated secondary SS was the rate of SDAI remission at 52 weeks after initiation of abatacept therapy. The secondary endpoints included that of Saxson's test and Schirmer's test. Adverse events during the study period were also analyzed. Results. Thirty-two patients (all females) were enrolled in this study. Interim analysis at 24 weeks included assessment of efficacy ( n = 31) and safety ( n = 32). The mean SDAI decreased from 19.8 ± 11.0 (± SD) at baseline to 9.9 ± 9.9 at 24 weeks ( P < 0.05). Patients with clinical remission, as assessed by SDAI, increased from 0 patient (0 week) to 8 patients (25.8%) at 24 weeks. Saliva volume (assessed by Saxson's test) increased slightly from 2232 ± 1908 (0 week) to 2424 ± 2004 (24 weeks) mg/2 min ( n = 29). In 11 patients with Greenspan grading 1/2 of labial salivary glands biopsy, saliva volume increased from 2945 ± 2090 (0 week) to 3419 ± 2121 (24 weeks) mg/2 min ( P < 0.05). Schirmer's test for tear volume showed increase from 3.6 ± 4.6 (0 week) to 5.5 ± 7.1 (24 weeks) mm/5 min ( n = 25; P < 0.05). Five adverse events occurred in five of 32 patients (15.6%), and three of these events were infections. Conclusion. Abatacept seems to be effective for both RA and RA-related secondary SS. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
9. Serum interferon-α is a useful biomarker in patients with anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis.
- Author
-
Horai, Yoshiro, Koga, Tomohiro, Fujikawa, Keita, Takatani, Ayuko, Nishino, Ayako, Nakashima, Yoshikazu, Suzuki, Takahisa, Kawashiri, Shin-ya, Iwamoto, Naoki, Ichinose, Kunihiro, Tamai, Mami, Nakamura, Hideki, Ida, Hiroaki, Kakugawa, Tomoyuki, Sakamoto, Noriho, Ishimatsu, Yuji, Mukae, Hiroshi, Hamaguchi, Yasuhito, Fujimoto, Manabu, and Kuwana, Masataka
- Subjects
INTERFERONS ,SERUM ,BIOMARKERS ,DERMATOMYOSITIS ,CELL differentiation ,INTERSTITIAL lung diseases - Abstract
Objective. We have tried to clarify the clinical importance of the measurement of serum type-I interferon (IFN) in patients with anti-melanoma differentiation-associated gene 5 Ab (MDA5 Ab)-positive dermatomyositis (DM). Methods. We studied 30 patients with DM: 10 were anti-MDA5 Ab-positive and 20 were anti-MDA5 Ab-negative. At each patient's initial visit, serum IFN-α, IFN-β, interleukin 18 (IL-18), ferritin, and the titer of anti-MDA5 Ab were measured using enzyme-linked immunosorbent assays (ELISAs). The associations between the IFNs and with the other variables were examined. Results. Rapidly progressive interstitial lung disease (RPILD) was confirmed in 10 patients, most of whom were complicated in the anti-MDA5 Ab-positive DM patients. The presence of clinically amyopathic dermatomyositis (CADM) as well as the serum concentrations of IFN-α and ferritin was significantly higher in the anti-MDA5 Ab-positive DM patients. Serum concentration of IL-18 did not differ between anti-MDA5 Ab-positive and anti-MDA5 Ab-negative groups; however, a positive correlation was found between IFN-α and IL-18 in the anti-MDA5 Ab-positive DM patients ( r = 0.8139, p = 0.0146). Conclusion. Serum IFN-α can be used as a useful biomarker in patients with anti-MDA5 Ab-positive DM, which may reflect the presence of RPILD. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
10. A case of microscopic polyangiitis in an elderly patient presenting predominantly with cholecystitis successfully treated with mizoribine.
- Author
-
Ichinose, Kunihiro, Iwanaga, Nozomi, Okada, Akitomo, Tamai, Mami, Yamasaki, Satoshi, Nakamura, Hideki, Origuchi, Tomoki, and Kawakami, Atsushi
- Subjects
CHOLECYSTITIS ,CHOLECYSTECTOMY ,VASCULITIS ,IMMUNOSUPPRESSIVE agents ,MYELOPEROXIDASE ,PREDNISOLONE - Abstract
An 82-year-old woman was previously diagnosed with cholecystitis and treated with antibiotics at another hospital. Because her fever and inflammation persisted, therapeutic cholecystectomy was performed. Histopathology of the gallbladder revealed periarterial vasculitis. After transfer to our hospital, an elevated titer of myeloperoxidase-antineutrophil cytoplasmic antibody (MPO-ANCA) was observed (47 U/mL). The patient's renal dysfunction had previously been thought to be sequelae of her cholecystectomy. We diagnosed microscopic polyangiitis (MPA) and began treatment with 40 mg orally of prednisolone daily. The titer of MPO-ANCA decreased with the treatment, but fever recurred with prednisolone taper. We, therefore, added 50 mg orally of mizoribine (MZR) daily as an immunosuppressant and increased the MZR to 100 mg daily while monitoring its blood peak concentration. The peak level of MZR was 1.58 μg/mL at 6 h after administration. After adding MZR, we successfully tapered the orally dosed prednisolone without recurrent fever or complications. We describe this case of MPA in an elderly patient manifesting predominantly with cholecystitis and successfully treated with orally dosed prednisolone and MZR. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
11. Ultrasonography as an additional item in the American College of Rheumatology classification of Sjögren’s syndrome.
- Author
-
Takagi, Yukinori, Sumi, Misa, Nakamura, Hideki, Iwamoto, Naoki, Horai, Yoshiro, Kawakami, Atsushi, and Nakamura, Takashi
- Published
- 2014
12. Synovial inflammation assessed by ultrasonography correlates with MRI-proven osteitis in patients with rheumatoid arthritis.
- Author
-
Kawashiri, Shin-ya, Suzuki, Takahisa, Nakashima, Yoshikazu, Horai, Yoshiro, Okada, Akitomo, Nishino, Ayako, Iwamoto, Naoki, Ichinose, Kunihiro, Arima, Kazuhiko, Tamai, Mami, Nakamura, Hideki, Origuchi, Tomoki, Uetani, Masataka, Aoyagi, Kiyoshi, Eguchi, Katsumi, and Kawakami, Atsushi
- Subjects
RHEUMATOID arthritis ,OSTEITIS ,SYNOVITIS ,ACADEMIC medical centers ,CHI-squared test ,MAGNETIC resonance imaging ,STATISTICS ,ULTRASONIC imaging ,DATA analysis ,DIAGNOSIS ,PROGNOSIS - Abstract
Objective. The aim of this study was to explore whether assessment of synovial inflammation by ultrasonography correlates with MRI-proven osteitis in patients with RA.Methods. Thirty RA patients who fulfilled 2010 RA classification criteria and were naive to DMARDs, including biologics and glucocorticoids, were consecutively enrolled in this study. Grey scale (GS) and power Doppler (PD) images of articular synovitis and bone erosion in both wrist and MCP joints were evaluated by the method proposed by the European League Against Rheumatism. MRI-proven osteitis of the identical sites was also evaluated within 3 days using the RA MRI scoring system (RAMRIS). The Cochran–Armitage test and Spearman’s correlation coefficient were used to investigate the correlation of each US finding with MRI-proven osteitis.Results. MRI-proven osteitis was found in 8.3% of MCP joints and 48.3% of wrist joints. Its prevalence was increased in the joints where the GS or PD grade of articular synovitis was 2 or 3. In addition, MRI-proven osteitis was found preferentially in the joints positive for bone erosion on US. A clear correlation was demonstrated between the GS or PD grade of articular synovitis or the presence of US bone erosion and RAMRIS osteitis score in both MCP joints and wrist joints.Conclusion. Our data indicate that joint injury assessed by US correlates with MRI-proven osteitis in patients with RA. [ABSTRACT FROM PUBLISHER]
- Published
- 2014
- Full Text
- View/download PDF
13. Presence of ultrasound subclinical synovitis and increment of serum vascular endothelial growth factor in a patient with rheumatoid arthritis achieved in sustained clinical remission by treatment with adalimumab and methotrexate.
- Author
-
Kawashiri, Shin-ya, Arima, Kazuhiko, Suzuki, Takahisa, Nakashima, Yoshikazu, Horai, Yoshiro, Okada, Akitomo, Tamai, Mami, Nakamura, Hideki, and Kawakami, Atsushi
- Subjects
SYNOVITIS ,SYNOVIAL membrane diseases ,VASCULAR endothelial growth factors ,RHEUMATOID arthritis ,METHOTREXATE - Abstract
A 63-year-old male Japanese rheumatoid arthritis (RA) patient, in whom treatment with infliximab and methotrexate (MTX) had once led to drug-free remission, experienced a disease flare in July 2010. He was retreated with a combination of adalimumab and MTX, and clinical remission was achieved in 3 months. In contrast, power Doppler signals by ultrasonography with increased serum vascular endothelial growth factor still remained after he achieved sustained clinical remission, whereas no radiographic progression has been found. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
14. Primary and secondary surveys on epidemiology of Sjögren's syndrome in Japan.
- Author
-
Tsuboi, Hiroto, Asashima, Hiromitsu, Takai, Chinatsu, Hagiwara, Shinya, Hagiya, Chihiro, Yokosawa, Masahiro, Hirota, Tomoya, Umehara, Hisanori, Kawakami, Atsushi, Nakamura, Hideki, Sano, Hajime, Tsubota, Kazuo, Ogawa, Yoko, Takamura, Etsuko, Saito, Ichiro, Inoue, Hiroko, Nakamura, Seiji, Moriyama, Masafumi, Takeuchi, Tsutomu, and Tanaka, Yoshiya
- Subjects
SJOGREN'S syndrome ,EPIDEMIOLOGY ,PATIENT satisfaction ,RHEUMATOLOGY ,THERAPEUTICS - Abstract
Objective. To characterize the epidemiology of Sjögren's syndrome (SS), including prevalence, disease type, extra-glandular involvement, satisfaction of diagnostic criteria sets, and treatment used in Japan. Methods. The Research Team for Autoimmune Diseases, the Research Program for Intractable Disease by the Ministry of Health, Labor and Welfare conducted primary and secondary surveys on epidemiology of SS in 2011. The primary survey covered 4,729 out of 14,095 Japan-wide Hospital Departments to investigate the prevalence of SS. The secondary survey encompassed 214 Hospital Departments that agreed to the survey, to characterize disease type, extra-glandular involvement, satisfaction of diagnostic criteria sets, and treatments. Results. The number of patients with SS in Japan estimated by the primary survey was 68,483. The secondary survey involving data collected from 2,195 SS patients from 98 Hospital Departments showed that the mean age of patients was 60.8 ± 15.2 years, male/female ratio was 1/17.4, primary/secondary SS was about 60%/40% and glandular/extra-glandular form in primary SS was about 70%/25%. The satisfaction rate was 53.8% for the 1999 revised Japanese Ministry of Health criteria for the diagnosis of SS, 47.7% for the 2002 American-European Consensus Group classification criteria for SS and 49.6% for 2012 American College of Rheumatology classification criteria for SS. Corticosteroids were used by 752 of 2,195 patients (34%), immunosuppressants by 358 patients (16%), biologics by 68 patients (3%) and secretagogues by 695 patients (32%). Conclusion. The surveys provided valuable information on the epidemiology of SS including prevalence, disease type, extra-glandular involvement, satisfaction of diagnostic criteria sets and treatments used today in Japan. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
15. Ultrasonographic examination of rheumatoid arthritis patients who are free of physical synovitis: power Doppler subclinical synovitis is associated with bone erosion.
- Author
-
Kawashiri, Shin-ya, Suzuki, Takahisa, Nakashima, Yoshikazu, Horai, Yoshiro, Okada, Akitomo, Iwamoto, Naoki, Ichinose, Kunihiro, Tamai, Mami, Arima, Kazuhiko, Nakamura, Hideki, Origuchi, Tomoki, Uetani, Masataka, Aoyagi, Kiyoshi, Eguchi, Katsumi, and Kawakami, Atsushi
- Subjects
DIAGNOSIS of bone diseases ,SYNOVITIS ,ACADEMIC medical centers ,DOPPLER ultrasonography ,CHI-squared test ,FISHER exact test ,RHEUMATOID arthritis ,STATISTICS ,U-statistics ,DATA analysis ,BLIND experiment ,SEVERITY of illness index ,DESCRIPTIVE statistics ,DISEASE complications ,DIAGNOSIS - Abstract
Objective. The aim of this study was to investigate the characteristics of power Doppler (PD) subclinical synovitis in patients with RA who achieve clinical remission free from physical synovitis.Methods. Twenty-nine RA patients were consecutively enrolled. All of the patients had achieved clinical remission [simplified disease activity index (SDAI) 3.3] for at least 6 months at the musculoskeletal ultrasound (MSKUS) examination. Additionally, none of the patients exhibited tender joints at 68 sites or swollen joints at 66 sites. MSKUS of bilateral wrist and finger joints, including the first to fifth MCP joints, the first IP joint and the second to fifth PIP joints, was performed and the findings obtained by grey scale (GS) and PD were graded on a semi-quantitative scale from 0 to 3.Results. The median disease duration upon the introduction of DMARDs was 3 months and that at MSKUS examination was 21 months. The percentages of patients with PD synovitis in at least one joint were PD grade 1, 58.6%; PD grade 2, 31.0% and PD grade 3, 6.9%. The use of biological agents was low in patients with PD synovitis grade 2 (P < 0.05). The presence of US bone erosion was high by patient (P < 0.05) and by joint (P < 0.0001) with PD synovitis as compared with those without PD synovitis. However, no correlations were found between PD synovitis measures and serum biomarkers, including angiogenesis factors.Conclusion. PD subclinical synovitis correlates with several clinical characteristics, whereas conventional serum biomarkers are not useful for indicating the presence of subclinical PD synovitis. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
16. A case of cutaneous polyarteritis nodosa with elevated serum interleukin-6 levels complicated by leg arterial stenosis and destructive arthropathy of the left ankle.
- Author
-
Horai, Yoshiro, Tokuyama, Ayuko, Sumiyoshi, Remi, Nakashima, Yoshikazu, Suzuki, Takahisa, Okada, Akitomo, Kawashiri, Shin-ya, Ichinose, Kunihiro, Izumi, Yasumori, Miyashita, Taiichiro, Tamai, Mami, Yamasaki, Satoshi, Nakamura, Hideki, Hayashi, Tomayoshi, Origuchi, Tomoki, and Kawakami, Atsushi
- Subjects
POLYARTERITIS nodosa ,INTERLEUKIN-6 ,BLOOD serum analysis ,ARTERIAL stenosis ,JOINT diseases ,LEG diseases ,ANKLE diseases - Abstract
We report a case of a 60-year-old female with cutaneous polyarteritis nodosa (CPN) of the left ankle, accompanied by elevated serum interleukin (IL)-6 levels. Computed tomographic angiography revealed severe narrowing of medium-sized arteries in her left leg. Destructive arthropathy in the left ankle was identified by X-ray and magnetic resonance imaging. This is the first Japanese case of severe CPN complicated by destructive arthropathy. Quantification of serum IL-6 might be useful in diagnosis and evaluation of CPN. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
17. An elderly patient with chronic active Epstein-Barr virus infection with mixed cryoglobulinemia and review of the literature.
- Author
-
Ichinose, Kunihiro, Origuchi, Tomoki, Tashiro, Naoki, Kawashiri, Shin-ya, Iwamoto, Naoki, Fujikawa, Keita, Aramaki, Toshiyuki, Arima, Kazuhiko, Tamai, Mami, Yamasaki, Satoshi, Nakamura, Hideki, Moriuchi, Hiroyuki, and Kawakami, Atsushi
- Subjects
OLDER patients ,EPSTEIN-Barr virus diseases ,CRYOGLOBULINEMIA ,MEDICAL literature reviews ,PARAPROTEINEMIA ,ONCOGENIC DNA viruses ,THROMBOCYTOPENIA - Abstract
A 76-year-old woman was diagnosed with chronic active Epstein-Barr virus (EBV) infection (CAEBV) with sustained fever, anemia, numbness of the lower limbs, and liver dysfunction. The patient had an unusual anti-EBV antibody profile and high viral load, positive rheumatoid factor, and cryoglobulinemia. She suffered from recurrent hemosputum with pleural effusion and thrombocytopenia caused by CAEBV infection, and she died in July 2008. Here, we present a rare case of CAEBV infection with cryoglobulinemia in an elderly patient. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
18. Takayasu arteritis developing during treatment of ulcerative colitis with infliximab.
- Author
-
Horai, Yoshiro, Satoru, Oka, Lapalme-Remis, Samuel, Sumiyoshi, Remi, Nakashima, Yoshikazu, Suzuki, Takahisa, Okada, Akitomo, Kawashiri, Shin-ya, Ichinose, Kunihiro, Tamai, Mami, Yamasaki, Satoshi, Nakamura, Hideki, Takeshima, Fuminao, Origuchi, Tomoki, and Kawakami, Atsushi
- Subjects
TAKAYASU arteritis ,COLITIS treatment ,ULCERATIVE colitis ,INFLIXIMAB ,YOUNG women ,PREDNISOLONE ,NECK pain ,C-reactive protein ,DISEASES - Abstract
A 22-year-old female with ulcerative colitis that was successfully treated with infliximab (IFX), and remained stable following tapered discontinuation of prednisolone, developed anterior neck pain and elevation of C-reactive protein following her fourth administration of IFX. She was diagnosed with Takayasu arteritis (TA) based on neck ultrasound and computed tomography angiography. This is the first report describing the development of TA during treatment of UC with IFX. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
19. Usefulness of ultrasonography-proven tenosynovitis to monitor disease activity of a patient with very early rheumatoid arthritis treated by abatacept.
- Author
-
Kawashiri, Shin-ya, Fujikawa, Keita, Nishino, Ayako, Suzuki, Takahisa, Okada, Akitomo, Nakamura, Hideki, and Kawakami, Atsushi
- Subjects
DIAGNOSTIC ultrasonic imaging ,TENOSYNOVITIS ,PATIENT monitoring ,RHEUMATOID arthritis treatment ,ABATACEPT ,DISEASE remission ,ADVERSE health care events - Abstract
We introduced abatacept (ABT) in a very early rheumatoid arthritis (RA) patient with active tenosynovitis of hands defined by musculoskeletal ultrasonography (MSKUS). MSKUS-proven tenosynovitis remarkably improved at 2 months in spite of clinical exacerbation, followed by clinical remission at 5 months. MSKUS abnormalities also disappeared. Although ABT was discontinued due to an adverse event after the sixth infusion, she remained in clinical remission as well as imaging remission by MSKUS at 13 months. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
20. Validation of different sets of criteria for the diagnosis of Sjögren's syndrome in Japanese patients.
- Author
-
Tsuboi, Hiroto, Hagiwara, Shinya, Asashima, Hiromitsu, Umehara, Hisanori, Kawakami, Atsushi, Nakamura, Hideki, Sano, Hajime, Tsubota, Kazuo, Ogawa, Yoko, Takamura, Etsuko, Saito, Ichiro, Inoue, Hiroko, Nakamura, Seiji, Moriyama, Masafumi, Takeuchi, Tsutomu, Tanaka, Yoshiya, Hirata, Shintaro, Mimori, Tsuneyo, Matsumoto, Isao, and Sumida, Takayuki
- Subjects
SJOGREN'S syndrome diagnosis ,SJOGREN'S syndrome ,JAPANESE people ,RHEUMATOLOGY ,AUTOIMMUNE diseases ,PHYSICIANS ,TECHNICAL specifications ,PATIENTS ,DISEASES - Abstract
Objective: To validate the revised Japanese Ministry of Health criteria for the diagnosis of Sjögren's syndrome (SS) (JPN) (1999), The American-European Consensus Group classification criteria for SS (AECG) (2002), and American College of Rheumatology classification criteria for SS (ACR) (2012). Methods: The study subjects were 694 patients with SS or suspected SS who were followed-up in June 2012 at ten hospitals that form part of the Research Team for Autoimmune Diseases, The Research Program for Intractable Disease by the Ministry of Health, Labor and Welfare (MHLW). All patients had been checked for all four criteria of the JPN (pathology, oral, ocular, anti-SS-A/SS-B antibodies). We studied the clinical diagnosis made by the physician in charge and the satisfaction of the above criteria. Results: Of the 694 patients, 499 patients did not have other connective tissue diseases (CTDs). SS was diagnosed in 476 patients (primary SS in 302, secondary SS in 174), whereas non-SS was diagnosed in 218 patients (without other CTDs in 197, with other CTDs in 21) by the physician in charge. The sensitivities of JPN, AECG, and ACR in the diagnosis of all forms of SS (both primary and secondary SS) were 79.6, 78.6, and 77.5 %, respectively, with respective specificities of 90.4, 90.4, and 83.5 %. The sensitivities of the same systems in the diagnosis of primary SS were 82.1, 83.1, and 79.1 %, respectively, with specificities of 90.9, 90.9, and 84.8 %, respectively. The sensitivities of the same systems in the diagnosis of secondary SS were 75.3, 70.7, and 74.7 %, respectively, with specificities of 85.7, 85.7, and 71.4 %, respectively. Conclusion: The sensitivity of JPN to all forms of SS and secondary SS, the sensitivity of AECG to primary SS, and the specificities of JPN and AECG for all forms of SS, primary SS, and secondary SS were highest in the diagnosis of SS in Japanese patients. These results indicate that the JPN criteria for the diagnosis of SS in Japanese patients are superior to ACR and AECG. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
21. Significant improvement in MRI-proven bone edema is associated with protection from structural damage in very early RA patients managed using the tight control approach.
- Author
-
Kita, Junko, Tamai, Mami, Arima, Kazuhiko, Kawashiri, Shin-ya, Horai, Yoshiro, Iwamoto, Naoki, Okada, Akitomo, Koga, Tomohiro, Nakashima, Yoshikazu, Suzuki, Takahisa, Yamasaki, Satoshi, Nakamura, Hideki, Origuchi, Tomoki, Ida, Hiroaki, Aoyagi, Kiyoshi, Uetani, Masataka, Eguchi, Katsumi, and Kawakami, Atsushi
- Subjects
MAGNETIC resonance imaging ,RHEUMATOID arthritis ,EDEMA ,BONE diseases ,FINGER joint ,DISEASE remission ,DISEASE progression ,PREVENTIVE medicine ,PATIENTS - Abstract
Objective: To identify the value of magnetic resonance imaging (MRI)-proven bone edema in patients with very early rheumatoid arthritis (RA). Methods: All of the 13 patients included in the study were positive at entry for MRI-proven bone edema of the wrist and finger joints and anti-cyclic citrullinated peptide antibodies or IgM-rheumatoid factor. A tight control approach was applied for 12 months. Plain MRI and radiographs of both wrist and finger joints were examined every 6 months. MRI was scored by the RA MRI scoring (RAMRIS) technique and plain radiographs were scored using the Genant-modified Sharp score. Variables that were correlated with plain radiographic changes at 12 months were examined. Results: Simplified disease activity index (SDAI) remission was achieved in 7 patients, and a significant reduction in the RAMRIS bone edema score, which declined to <33 % as compared with the baseline, was achieved in 8 out of 13 patients. Four patients showed plain radiographic progression while 9 patients did not. Significant reductions in the RAMRIS bone edema score ( p = 0.007) and the time-integrated SDAI ( p = 0.031) were the variables involved in plain radiographic progression. Conclusions: Improvement in bone edema may be associated with protection against structural damage in very early RA patients managed using the tight control approach. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
22. HTLV-I virological and histopathological analysis in two cases of anti-centromere-antibody-seropositive Sjögren's syndrome.
- Author
-
Nakamura, Hideki, Horai, Yoshiro, Tokuyama, Ayuko, Yoshimura, Shunsuke, Nakajima, Hideki, Ichinose, Kunihiro, Yamasaki, Satoshi, Nakamura, Tatsufumi, Hayashi, Tomayoshi, and Kawakami, Atsushi
- Subjects
- *
HTLV-I , *VIROLOGY , *HISTOPATHOLOGY , *CENTROMERE , *IMMUNOGLOBULINS , *CYTOKINES , *TRANSFORMING growth factors , *SJOGREN'S syndrome - Abstract
Introduction: The aim of this study was to show the clinical and pathological characteristics of anti-centromere-antibody (ACA)-seropositive Sjögren's syndrome (SS) in two anti-human T-cell leukemia virus type I (HTLV-I)-seropositive patients. Methods: One patient was an HTLV-I carrier whereas the other was diagnosed with HTLV-I-associated myelopathy (HAM). Background data including serum HTLV-I titers, viral loads, and cytokine profiles were recorded. Azocarmine with aniline blue (Azan)-Mallory staining and immunohistochemistry of the labial salivary glands (LSGs) and a muscle biopsy specimen from the HAM patient were performed. Results: Serum transforming growth factor beta (TGF-β), tumor necrosis factor alpha (TNF-α), and HTLV-I viral load were high in the HAM-SS patient compared with the HTLV-I carrier. Fibrous change in LSG was prominent in the HAM-SS patient. Although TGF-β expression was similar in the two patients, expression of HTLV-I-related proteins including p12, p28, group-specific antigen (GAG), and nuclear factor kappa-B (NF-κB) in the LSG were dominantly detected in the HAM-SS patient. Frequency of TGF-β staining in HTLV-I-seropositive SS patients without ACA, HTLV-I-seronegative SS patients with ACA, and HTLV-I-seronegative SS patients without ACA was lower than that of the previous two patients. Conclusion: A high HTLV-I viral load in situ is supposed to promote the production of cytokines, especially TGF-β, resulting in the fibrous change of LSG in ACA-seropositive SS patients. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
23. Early diagnosis and treatment for remission of clinically amyopathic dermatomyositis complicated by rapid progress interstitial lung disease: a report of two cases.
- Author
-
Horai, Yoshiro, Isomoto, Eriko, Koga, Tomohiro, Okada, Akitomo, Kawashiri, Shin-ya, Tamai, Mami, Yamasaki, Satoshi, Nakamura, Hideki, Origuchi, Tomoki, Hamaguchi, Yasuhito, Fujimoto, Manabu, Kuwana, Masataka, and Kawakami, Atsushi
- Subjects
EARLY diagnosis ,DISEASE remission ,DERMATOMYOSITIS ,MUSCLE weakness ,INTERSTITIAL lung diseases ,IMMUNOSUPPRESSIVE agents ,SYMPTOMS ,THERAPEUTICS - Abstract
We report two cases of clinically amyopathic dermatomyositis (CADM) complicated by rapid progress interstitial lung disease (RPILD). The diagnosis of CADM was based on Gottron's papule and RPILD, and the absence of muscle weakness. The female patients were treated with early immunosuppressive therapies including steroid pulse therapy, resulting in significant improvement in respiratory symptoms, clinical data, and imaging. Measurement of anti-CADM-140/MDA5 antibody was useful for obtaining a definitive diagnosis of CADM in these cases. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
24. Musculoskeletal ultrasonography assists the diagnostic performance of the 2010 classification criteria for rheumatoid arthritis.
- Author
-
Kawashiri, Shin-ya, Suzuki, Takahisa, Okada, Akitomo, Yamasaki, Satoshi, Tamai, Mami, Nakamura, Hideki, Origuchi, Tomoki, Mizokami, Akinari, Uetani, Masataka, Aoyagi, Kiyoshi, Eguchi, Katsumi, and Kawakami, Atsushi
- Subjects
MUSCULOSKELETAL system diseases ,ULTRASONIC imaging ,PERFORMANCE evaluation ,RHEUMATOID arthritis diagnosis ,DOPPLER ultrasonography ,MAGNETIC resonance imaging - Abstract
Objective: We investigated whether musculoskeletal ultrasonography (MSKUS) assists the diagnostic performance of the 2010 rheumatoid arthritis (RA) classification criteria. Methods: Sixty-nine early arthritis patients were consecutively enrolled. None of the patients had been treated. In MSKUS of bilateral wrist and finger joints from 22 sites, the findings obtained by gray-scale and power Doppler (PD) assessment were graded on a semiquantitative scale from 0 to 3. Plain magnetic resonance imaging (MRI) of both wrist and finger joints was also examined. Diagnosis of RA was defined by the initiation of disease-modifying antirheumatic drugs within the first 3 months. The diagnostic performance of the patients was evaluated at entry using 2010 RA classification criteria in conjunction with MSKUS. Results: The indispensable MSKUS finding for differentiating RA was the presence of a PD grade 2 or 3 that was superior to 2010 RA classification criteria or MRI-proven bone edema. We propose that the decision tree algorithm of 2010 RA classification criteria with PD grade 2 or 3 reveals the best discriminative ability. Conclusion: MSKUS, especially with a strong PD signal, is very useful to assist the diagnostic performance of the 2010 RA classification criteria in the early recognition of RA. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
25. A case of IgG4-related pulmonary disease with rapid improvement.
- Author
-
Umeda, Masataka, Fujikawa, Keita, Origuchi, Tomoki, Tsukada, Toshiaki, Kondo, Akira, Tomari, Shinya, Inoue, Yuichi, Soda, Hisashi, Nakamura, Hideki, Matsui, Shoko, and Kawakami, Atsushi
- Subjects
IMMUNOGLOBULIN G ,LUNG diseases ,OLDER men ,COUGH ,CHEST examination ,TOMOGRAPHY ,PLASMA cells ,PREDNISOLONE ,DISEASES in older people - Abstract
We report a 72-year-old man with respiratory involvement of immunoglobulin G4 (IgG4)-related disease, who developed dry cough and shortness of breath on effort. The chest computed tomography scan image showed massive and diffuse ground-glass opacity, interlobular thickening, and bronchial wall thickening. The infiltration of IgG4-positive plasma cells in the transbronchial lung biopsy and high serum IgG4 concentrations were found. The patient was treated with 0.6 mg/kg oral prednisolone and showed rapid improvement. This is a case of IgG4-related disease in which the only complication was respiratory involvement. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
26. Magnetic resonance imaging (MRI) detection of synovitis and bone lesions of the wrists and finger joints in early-stage rheumatoid arthritis: comparison of the accuracy of plain MRI-based findings and gadolinium-diethylenetriamine pentaacetic acid-enhanced MRI-based findings
- Author
-
Tamai, Mami, Kawakami, Atsushi, Uetani, Masataka, Fukushima, Aya, Arima, Kazuhiko, Fujikawa, Keita, Iwamoto, Naoki, Aramaki, Toshiyuki, Kamachi, Makoto, Nakamura, Hideki, Ida, Hiroaki, Origuchi, Tomoki, Aoyagi, Kiyoshi, and Eguchi, Katsumi
- Subjects
MAGNETIC resonance imaging ,SYNOVITIS ,WRIST diseases ,FINGER joint ,RHEUMATOID arthritis ,GADOLINIUM compounds ,DISEASES ,DIAGNOSIS - Abstract
Objective: To explore whether synovitis and bone lesions in the wrists and finger joints visualized by plain magnetic resonance imaging (MRI)-based findings correspond exactly or not to those judged by gadolinium-diethylenetriamine pentaacetic acid (Gd-DTPA)-enhanced MRI-based findings. Methods: Magnetic resonance imaging of the wrists and finger joints of both hands were examined in 51 early-stage rheumatoid arthritis (RA) patients whose median disease duration from the onset of articular manifestations to entry was 5 months, by both plain (T1 and short-time inversion recovery images) and Gd-DTPA-enhanced MRI (post-contrast fat-suppressed T1-weighted images) simultaneously. We focused on 15 sites per hand, to examine the presence of synovitis and bone lesions (bone edema and bone erosion). Gd-DTPA-enhanced MRI-based findings were considered 'true' lesions, and we evaluated the accuracy of plain MRI-based findings in comparison to Gd-DTPA-enhanced MRI-based findings. Results: Synovitis, judged by plain MRI-based findings, appeared as false-positive at pretty frequency; thus, the specificity, positive predictive value and accuracy of the findings were low. The rate of enhancement (E-rate) in false-positive synovitis sites was significantly low compared with true-positive synovitis sites where Gd-DTPA enhancement appears. In contrast to synovitis, the false-positivity of bone lesions, judged by plain MRI-based findings, was very low compared with Gd-DTPA-enhanced MRI-based findings. Conclusion: Synovitis judged by plain MRI-based findings is sometimes considered false-positive especially in sites where synovitis is mild. However, plain MRI is effective in identifying bone lesions in the wrist and finger joints in early-stage RA. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
27. High serum matrix metalloproteinase 3 is characteristic of patients with paraneoplastic remitting seronegative symmetrical synovitis with pitting edema syndrome.
- Author
-
Origuchi, Tomoki, Arima, Kazuhiko, Kawashiri, Shin-ya, Tamai, Mami, Yamasaki, Satoshi, Nakamura, Hideki, Tsukada, Toshiaki, Aramaki, Toshiyuki, Furuyama, Masako, Miyashita, Taiichiro, Kawabe, Yojiro, Iwanaga, Nozomi, Terada, Kaoru, Ueki, Yukitaka, Fukuda, Takaaki, Eguchi, Katsumi, and Kawakami, Atsushi
- Subjects
BLOOD serum analysis ,MATRIX metalloproteinases ,PARANEOPLASTIC syndromes ,SYNOVITIS ,EDEMA ,RETROSPECTIVE studies ,ADRENOCORTICAL hormones - Abstract
Recently, it was reported that remitting seronegative symmetrical synovitis with pitting edema (RS3PE) syndrome could be complicated with solid tumors. In a retrospective, multicenter study between October, 2003 and September, 2010, we investigated the characteristics of patients with paraneoplastic RS3PE syndrome who fulfilled following criteria: (1) bilateral pitting edema of hands or feet or both, (2) sudden onset of polyarthritis, and (3) age >50 years, (4) seronegativity for rheumatoid factor (RF). A total of 33 cases fulfilled the above criteria. Eight patients (seven men and one woman) developed cancer within 2 years of RS3PE syndrome onset. There was no significant difference between the neoplastic and nonneoplastic groups in the proportions of patients with fever, symmetrical polyarthritis, pitting edema, and good response to corticosteroids. Serum matrix metalloproteinase 3 (MMP-3) level (median 437.3 ng/ml) in the paraneoplastic RS3PE patients was significantly higher than that in patients without neoplasia (median 114.7 ng/ml) ( p < 0.05). We found that high serum MMP-3 is characteristic of patients with paraneoplastic RS3PE syndrome. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
28. The diagnostic utility of anti-melanoma differentiation-associated gene 5 antibody testing for predicting the prognosis of Japanese patients with DM.
- Author
-
Koga, Tomohiro, Fujikawa, Keita, Horai, Yoshiro, Okada, Akitomo, Kawashiri, Shin-ya, Iwamoto, Naoki, Suzuki, Takahisa, Nakashima, Yoshikazu, Tamai, Mami, Arima, Kazuhiko, Yamasaki, Satoshi, Nakamura, Hideki, Origuchi, Tomoki, Hamaguchi, Yasuhito, Fujimoto, Manabu, Ishimatsu, Yuji, Mukae, Hiroshi, Kuwana, Masataka, Kohno, Shigeru, and Eguchi, Katsumi
- Published
- 2012
29. Treatment discontinuation in patients with very early rheumatoid arthritis in sustained simplified disease activity index remission after synthetic disease-modifying anti-rheumatic drug administration.
- Author
-
Kita, Junko, Tamai, Mami, Arima, Kazuhiko, Nakashima, Yoshikazu, Suzuki, Takahisa, Kawashiri, Shin-ya, Iwamoto, Naoki, Okada, Akitomo, Koga, Tomohiro, Yamasaki, Satoshi, Nakamura, Hideki, Origuchi, Tomoki, Ida, Hiroaki, Aoyagi, Kiyoshi, Uetani, Masataka, Eguchi, Katsumi, and Kawakami, Atsushi
- Subjects
RHEUMATOID arthritis ,ANTIRHEUMATIC agents ,DRUG administration ,MAGNETIC resonance imaging ,AUTOANTIBODIES ,CLINICAL trials ,FOLLOW-up studies (Medicine) - Abstract
We aimed to identify whether drug-free remission could be achieved in patients with very early rheumatoid arthritis (RA) with poor prognosis factors by treatment with synthetic disease-modifying antirheumatic drugs (DMARDs). Thirteen patients with very early RA, whose disease was considered to have highly erosive potential, were included. Magnetic resonance imaging (MRI)-proven bone edema and autoantibodies were determined in these patients. A treat-to-target strategy initiated with synthetic DMARDs was employed for 12 months. If the patients achieved simplified disease activity index (SDAI) remission along with a reduction of the RA MRI scoring bone edema score to <33% as compared with baseline at 12 months, DMARD treatment was stopped and the clinical status was further observed for the following 12 months. Synthetic DMARDs were stopped at 12 months in 5 patients. One of the 5 was lost to follow-up because of sustaining an injury that required orthopedic surgery. Three of the remaining 4 patients showed continued SDAI remission that was DMARD-free without any evidence of radiographic progression for the following 12 months. Although this was a small clinical trial, we have shown-for the first time-that true remission of very early RA with poor prognosis factors can be achieved by treatment with synthetic DMARDs. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
30. A patient with systemic lupus erythematosus who developed massive small intestinal hemorrhaging during treatment for chronic lupus peritonitis.
- Author
-
Kawashiri, Shin-ya, Nishino, Ayako, Sueyoshi, Eijun, Okada, Akitomo, Koga, Tomohiro, Yamasaki, Satoshi, Nakamura, Hideki, Origuchi, Tomoki, and Kawakami, Atsushi
- Subjects
SYSTEMIC lupus erythematosus ,PERITONITIS ,ADRENOCORTICAL hormones ,TACROLIMUS ,METHYLPREDNISOLONE ,ANGIOGRAPHY ,THERAPEUTIC embolization - Abstract
A 50-year-old Japanese woman, a patient with systemic lupus erythematosus (SLE) complicated with chronic lupus peritonitis, developed massive small intestinal hemorrhaging. She was treated with intravenous pulse of methylprednisolone, intravenous pulse of cyclophosphamide (IVCY), and immunoabsorption, but the peritonitis was refractory to these treatments. Subsequently, she was treated with oral corticosteroid and tacrolimus, and received IVCY monthly, but she developed massive small intestinal hemorrhaging 1 year after. Abdominal angiography detected multiple bleeding sites from the jejunal and ileal arteries. After transarterial embolization treatment, the melena disappeared. The pathology of this case appeared to be lupus mesenteric vasculitis. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
31. Delayed treatment with tumor necrosis factor inhibitors in incomplete responders to synthetic disease-modifying anti-rheumatic drugs shows an excellent effect in patients with very early rheumatoid arthritis with poor prognosis factors.
- Author
-
Kita, Junko, Tamai, Mami, Arima, Kazuhiko, Nakashima, Yoshikazu, Suzuki, Takahisa, Kawashiri, Shin-ya, Okada, Akitomo, Koga, Tomohiro, Yamasaki, Satoshi, Nakamura, Hideki, Origuchi, Tomoki, Aramaki, Toshiyuki, Nakashima, Munetoshi, Fujikawa, Keita, Tsukada, Toshiaki, Ida, Hiroaki, Aoyagi, Kiyoshi, Uetani, Masataka, Eguchi, Katsumi, and Kawakami, Atsushi
- Subjects
TUMOR necrosis factors ,RHEUMATOID arthritis treatment ,IMMUNOGLOBULIN M ,DISEASE duration ,INFLIXIMAB ,ETANERCEPT ,DISEASE remission - Abstract
We aimed to investigate whether delayed treatment with tumor necrosis factor (TNF) inhibitors in incomplete responders to synthetic disease-modifying anti-rheumatic drugs (DMARDs) was effective among patients with very early rheumatoid arthritis (RA) with poor prognosis factors. We examined 22 patients with very early RA who were positive for anti-cyclic citrullinated peptide antibodies or IgM-rheumatoid factor. The mean disease duration at entry was 14.1 weeks. A treat-to-target strategy, aiming at simplified disease activity index (SDAI) remission, was initiated with synthetic DMARDs. SDAI remission was not achieved in 9 of the 22 patients with synthetic DMARDs alone, and TNF inhibitors were added in these patients. SDAI values in these 9 patients were further examined for the following 6 months. The TNF inhibitors (infliximab 8, etanercept 1) were added at a mean interval of 34.1 weeks after the initiation of synthetic DMARDs. SDAI remission was achieved in 4 of the 9 patients (44.4%) at 3 months and in 8 of the 9 patients (88.9%) at 6 months after the introduction of the TNF inhibitors. Radiographic damage had not progressed in these patients. Delayed treatment with TNF inhibitors is effective and tolerable for patients with very early RA with poor prognosis factors. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
32. Efficacy of adalimumab for a refractory case of relapsing polychondritis with reduction of pro-inflammatory cytokines.
- Author
-
Nakamura, Hideki, Suzuki, Takahisa, Nagaoka, Kentaro, Yamasaki, Satoshi, Tamai, Mami, Hayashi, Tomayoshi, and Kawakami, Atsushi
- Subjects
- *
DRUG efficacy , *ADALIMUMAB , *DISEASE relapse , *CHONDROMALACIA , *CYTOKINES , *INFLAMMATION , *GLUCOCORTICOIDS , *TUMOR necrosis factors , *HOSPITAL admission & discharge - Abstract
A 68-year-old man with a fever of unknown origin was admitted to our hospital. Bilateral auricularis and nasal root inflammation, with auricular perichondritis positive for anti-type II collagen (CII) antibody, led to a diagnosis of relapsing polychondritis (RP). Because the patient was refractory for high-dose glucocorticoid therapy, adalimumab was used. After the initiation of 40 mg of adalimumab, a rapid improvement of clinical manifestations, with a reduction in tumor necrosis factor-alpha (TNF-α) and interleukin 6 (IL-6), together with a titer of anti-CII antibody was observed. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
33. A case of Sjögren syndrome with pulmonary amyloidosis complicating microscopic polyangiitis.
- Author
-
Kawashiri, Shin-ya, Tamai, Mami, Yamasaki, Satoshi, Nakamura, Hideki, Kakugawa, Tomoyuki, Sakamoto, Noriho, Ishimatsu, Yuji, and Kawakami, Atsushi
- Subjects
SJOGREN'S syndrome ,AMYLOIDOSIS ,POLYARTERITIS nodosa ,DISEASES in older women ,DISEASE complications ,TOMOGRAPHY ,LUNG biopsy ,PARESTHESIA - Abstract
We present the case of a 71-year-old Japanese woman with Sjögren syndrome complicated with pulmonary amyloidosis who developed microscopic polyangiitis. She was admitted because of fever, weight loss, and paresthesia of the plantae and fingers. Chest computed tomography revealed bilateral multiple nodules with calcification in the lung. Transbronchial lung biopsy specimens showed AL-type (primary) amyloid deposits. The patient also tested positive for myeloperoxidase-antineutrophil cytoplasmic antibodies (MPO-ANCA), with changes in the MPO-ANCA titer that paralleled changes in the symptoms. Nerve conduction velocity findings showed mononeuropathy multiplex. Livedo vasculitis was observed on bilateral lower legs, and skin biopsy showed leukoclastic vasculitis. We diagnosed the patient as having microscopic polyangiitis. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
34. Successful treatment of a patient with IgG4-related disease with a paravertebral mass lesion.
- Author
-
Nakamura, Hideki, Hisatomi, Keiko, Koga, Tomohiro, Mizokami, Akinari, Yamasaki, Satoshi, Tamai, Mami, Origuchi, Tomoki, Irie, Junji, and Kawakami, Atsushi
- Subjects
- *
IMMUNOGLOBULIN G , *LACRIMAL apparatus , *BIOPSY , *PLASMA cells , *POSITRON emission tomography , *PREGNANE , *IMMUNOHISTOCHEMISTRY - Abstract
A 68-year-old woman was admitted with bleary eyes and lacrimal gland swelling. A biopsy specimen from a right paravertebral mass lesion detected by computed tomography showed remarkable IgG4-positive plasma cells. Because serum IgG4 was elevated to 3300 mg/dl, IgG4-related disease was diagnosed, with the assistance of fluorodeoxyglucose positron emission tomography (FDG-PET)/computed tomography (CT). Administration of 30 mg of oral prednisolone effectively reduced the lacrimal gland swelling and paravertebral mass volume. Nine months after the initiation of prednisolone, serum IgG4 was reduced to 31.4 mg/dl, and there was norecurrence. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
35. Disease activity score 28 may overestimate the remission induction of rheumatoid arthritis patients treated with tocilizumab: comparison with the remission by the clinical disease activity index.
- Author
-
Kawashiri, Shin-ya, Kawakami, Atsushi, Iwamoto, Naoki, Fujikawa, Keita, Aramaki, Toshiyuki, Tamai, Mami, Yamasaki, Satoshi, Nakamura, Hideki, Ueki, Yukitaka, Migita, Kiyoshi, Mizokami, Akinari, Origuchi, Tomoki, Aoyagi, Kiyoshi, and Eguchi, Katsumi
- Subjects
RHEUMATOID arthritis ,MONOCLONAL antibodies ,DRUG efficacy ,ERYTHROCYTES ,INFLIXIMAB ,DRUG therapy ,ACUTE phase proteins ,HEALTH outcome assessment ,PATIENTS - Abstract
We evaluated the efficacy of tocilizumab (TCZ) in patients with rheumatoid arthritis (RA) by the clinical disease activity index (CDAI) and disease activity score (DAS) 28-erythrocyte sedimentation rate (ESR). Thirty-two RA patients received 8 mg/kg of TCZ intravenously every 4 weeks for 48 weeks. The therapeutic response was also evaluated in 30 RA patients treated with 3 mg/kg of infliximab (IFX) for 46 weeks. We compared the therapeutic course of TCZ with IFX in order to evaluate the efficacy of TCZ therapy. A strong positive correlation between CDAI and DAS28-ESR was observed at baseline, whereas their associations dropped significantly within the first 2 months. The association recovered to the baseline by IFX, but still remained low in TCZ. Although a decrement of DAS28-ESR was prominent in TCZ as compared with IFX, that of CDAI was significant in the early phase and even in the latter in patients treated by IFX. The present study revealed that DAS28-ESR may not be sufficient to estimate RA disease activity treated by TCZ, probably due to the significant effect toward inhibition of acute phase reactants by TCZ. CDAI is suggested to be an important alternate of composite measure in these cases. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
36. In rheumatoid arthritis patients treated with tocilizumab, the rate of clinical disease activity index (CDAI) remission at 24 weeks is superior in those with higher titers of IgM-rheumatoid factor at baseline.
- Author
-
Kawashiri, Shin-ya, Kawakami, Atsushi, Iwamoto, Naoki, Fujikawa, Keita, Aramaki, Toshiyuki, Tamai, Mami, Yamasaki, Satoshi, Nakamura, Hideki, Origuchi, Tomoki, Ueki, Yukitaka, Migita, Kiyoshi, Mizokami, Akinari, Aoyagi, Kiyoshi, and Eguchi, Katsumi
- Subjects
MONOCLONAL antibodies ,RHEUMATOID arthritis ,TUMOR necrosis factors ,RHEUMATOID factor ,GLUCOCORTICOIDS ,METHOTREXATE ,CANCER chemotherapy ,DISEASE relapse ,PATIENTS - Abstract
We aimed to evaluate the efficacy of tocilizumab in patients with rheumatoid arthritis (RA), using the clinical disease activity index (CDAI), and to determine the baseline variables associated with CDAI remission. Fifty-eight patients with active RA were enrolled. We tried to evaluate whether baseline variables were associated with CDAI remission at 24 weeks. Twenty-two of the 58 patients (37.9%) had received tumor necrosis factor (TNF) inhibitors. The continuation rate of tocilizumab at 24 weeks was 87.9%. The seropositivity rates of IgM-rheumatoid factor (RF) and anti-cyclic citrullinated peptide (anti-CCP) antibodies at baseline were both 91.4%. The rate of CDAI remission at 24 weeks was 20.7%. We selected baseline variables including age, gender, duration of disease, concomitant use of glucocorticoids, concomitant use of methotrexate (MTX), previous anti-TNF therapy, titer of anti-CCP antibodies (high or low toward median), titer of IgM-RF (high or low toward median), and CDAI, and found that a high titer of IgM-RF was the only variable to be associated with CDAI remission, according to univariate and logistic regression analyses. This is a new finding, and may be specific to tocilizumab as compared with previous observations in anti-TNF therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
37. Contribution of an adenine to guanine single nucleotide polymorphism of the matrix metalloproteinase-13 ( MMP- 13) −77 promoter region to the production of anticyclic citrullinated peptide antibodies in patients with HLA-DRB1*shared epitope-negative rheumatoid arthritis
- Author
-
Iwamoto, Naoki, Kawakami, Atsushi, Arima, Kazuhiko, Tamai, Mami, Nakamura, Hideki, Kawashiri, Shin-ya, Kita, Junko, Okada, Akitomo, Koga, Tomohiro, Kamachi, Makoto, Yamasaki, Satoshi, Ichinose, Kunihiro, Ida, Hiroaki, Origuchi, Tomoki, and Eguchi, Katsumi
- Subjects
ADENINE ,NUCLEOTIDE sequence ,METALLOPROTEINASES ,HLA histocompatibility antigens ,GENETIC polymorphisms ,RHEUMATOID arthritis ,DISEASE susceptibility ,GENETIC markers - Abstract
We examined whether matrix metalloproteinase-13 (MMP-13) contributes to disease susceptibility or severity of rheumatoid arthritis (RA). Eighty-seven patients with RA whose disease duration was <2 years and 71 healthy controls were enrolled in the study. Adenine (A) to guanine (G) single nucleotide polymorphism (SNP) of the −77 MMP- 13 promoter region in RA and healthy controls was determined by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) technique. Human leukocyte antigen (HLA)-DRB1 genotyping was also performed using the same populations. Anticyclic citrullinated peptide (anti-CCP) antibodies from RA patients at entry were studied, and their relationships were examined. The genotype and allele frequency of SNP of MMP- 13 at −77 did not differ between RA patients and healthy controls. We focused on the RA patients who were negative for HLA-DRB1*shared epitope (SE) alleles and found that the seropositivity of anti-CCP antibodies with a titer >25 U/ml was high in the A/A genotype compared with the G/G genotype. The same characteristic was also found in HLA-DRB1*0405 allele-negative patients. Our data suggest that SNP of the −77 MMP- 13 promoter region acts as a surrogate marker of anti-CCP antibody production in HLA-DRB1*SE allele-negative RA patients, which may reflect RA severity. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
38. Reduction in serum levels of substance P in patients with rheumatoid arthritis by etanercept, a tumor necrosis factor inhibitor.
- Author
-
Origuchi, Tomoki, Iwamoto, Naoki, Kawashiri, Shin-ya, Fujikawa, Keita, Aramaki, Toshiyuki, Tamai, Mami, Arima, Kazuhiko, Nakamura, Hideki, Yamasaki, Satoshi, Ida, Hiroaki, Kawakami, Atsushi, Ueki, Yukitaka, Matsuoka, Naoki, Nakashima, Munetoshi, Mizokami, Akinari, Kawabe, Yojiro, Mine, Masanobu, Fukuda, Takaaki, and Eguchi, Katsumi
- Subjects
SERUM ,RHEUMATOID arthritis ,ETANERCEPT ,TUMOR necrosis factors ,SUBSTANCE P ,NEUROPEPTIDES ,PATIENTS - Abstract
We determined the effects of etanercept on the serum concentrations of neuropeptides in RA patients. In a total of 11 patients who had been injected with etanercept, the serum levels of substance P, calcitonin gene-related peptide (CGRP), and gastrin-releasing peptide (GRP) were analyzed. Average levels of serum substance P were significantly reduced from 1.53 to 0.62 ng/ml after the injection of etanercept. In the CGRP and GRP analyses, these average levels dropped from 1.57 and 0.51 ng/ml to 0.44 and 0.04 ng/ml, respectively. Etanercept appears to decrease substance P levels with an improvement in disease activities. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
39. The power Doppler ultrasonography score from 24 synovial sites or 6 simplified synovial sites, including the metacarpophalangeal joints, reflects the clinical disease activity and level of serum biomarkers in patients with rheumatoid arthritis.
- Author
-
Kawashiri, Shin-ya, Kawakami, Atsushi, Iwamoto, Naoki, Fujikawa, Keita, Satoh, Katsuya, Tamai, Mami, Nakamura, Hideki, Okada, Akitomo, Koga, Tomohiro, Yamasaki, Satoshi, Ida, Hiroaki, Origuchi, Tomoki, and Eguchi, Katsumi
- Subjects
RHEUMATOID arthritis ,DOPPLER ultrasonography ,BIOMARKERS ,STATISTICS ,U-statistics ,SYNOVITIS ,DATA analysis ,SEVERITY of illness index ,PROGNOSIS - Abstract
Objective. We evaluated the significance of the power Doppler ultrasonography (PDUS) score by comparing it with serum biomarkers and clinical disease activity.Methods. We measured the PDUS scores of 24 synovial sites in 12 joints in 22 RA patients. For convenience, the PDUS scores of six synovial sites in six joints were also examined. Each joint was scored for a power Doppler (PD) signal on a scale from 0 to 3. The PDUS scores are the sums of the PD signal scores for the 24 synovial sites or the 6 synovial sites. On the same day, serum variables as well as clinical disease activity were evaluated.Results. The PDUS scores from the 24 joint sites were significantly positively correlated with DAS of 28 joints (DAS-28), simplified disease activity index (SDAI), clinical disease activity index (CDAI) and serum biomarkers including MMP-3, VEGF and tissue inhibitor of metalloproteinases-1 (TIMP-1). Accordingly, the PDUS scores from the six synovial sites greatly correlated with those from the 24 joint sites. Clinical disease activities as well as serum variables were also clearly correlated with the PDUS scores from the six synovial sites.Conclusion. The standard as well as the simplified PDUS scores well reflected clinical disease activity and serum variables, including angiogenic factors. Our data reaffirm the utility of ultrasonography for monitoring disease activity in patients with RA. [ABSTRACT FROM PUBLISHER]
- Published
- 2011
- Full Text
- View/download PDF
40. Successful treatment of chronic lupus myocarditis with prednisolone and mizoribine.
- Author
-
Akazawa, Satoru, Ichinose, Kunihiro, Origuchi, Tomoki, Kawashiri, Shin-ya, Iwamoto, Naoki, Fujikawa, Keita, Aramaki, Toshiyuki, Kamachi, Makoto, Arima, Kazuhiko, Tamai, Mami, Nakamura, Hideki, Ida, Hiroaki, Kawakami, Atsushi, and Eguchi, Katsumi
- Subjects
TREATMENT of myocarditis ,SYSTEMIC lupus erythematosus ,HEART failure ,HEART biopsy ,IMMUNOSUPPRESSIVE agents ,DRUG efficacy ,CASE studies - Abstract
36-year-old female patient who was diagnosed with chronic myocarditis as an initial manifestation of systemic lupus erythematosus (SLE) was admitted to our hospital. At her third occurrence of heart failure, we performed an endomyocardial biopsy and proved chronic myocarditis with SLE. Subsequently, she was treated with prednisolone and the immunosuppressive agent mizoribine (MZR), and her cardiac function improved. We describe for the first time treatment with MZR for chronic cardiac involvement of SLE. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
41. Long-term efficacy of intravenously administered immunoglobulin in a case of polymyositis with limited application of steroid therapy.
- Author
-
Nakamura, Hideki, Fujikawa, Keita, Kawakami, Atsushi, Tamai, Mami, Yamasaki, Satoshi, Ida, Hiroaki, and Eguchi, Katsumi
- Subjects
- *
IMMUNOGLOBULINS , *PNEUMONIA , *ENZYMES , *POLYMYOSITIS , *CYCLIC peptides , *MAGNETIC resonance imaging - Abstract
72-year-old man who had been diagnosed with polymyositis (PM) was admitted to our hospital for pneumonia with exacerbation of muscle weakness, elevation of muscle enzymes, and positive magnetic resonance imaging findings. The patient had been refractory to cyclosporine A or azathioprine and hoped to avoid administration of high-dose steroids; IV immunoglobulin (IVIG) was therefore administered after improvement of the pneumonia. Two weeks after the IVIG therapy, muscle test scores, activities of daily living, and muscle enzymes were drastically improved. Twenty months after IVIG, no relapse of PM was observed. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
42. Regulation of disease susceptibility and mononuclear cell infiltration into the labial salivary glands of Sjögren’s syndrome by monocyte chemotactic protein-1.
- Author
-
Iwamoto, Naoki, Kawakami, Atsushi, Arima, Kazuhiko, Nakamura, Hideki, Kawashiri, Shin-ya, Tamai, Mami, Kita, Junko, Okada, Akitomo, Koga, Tomohiro, Kamachi, Makoto, Yamasaki, Satoshi, Ichinose, Kunihiro, Ida, Hiroaki, Origuchi, Tomoki, and Eguchi, Katsumi
- Subjects
DISEASE susceptibility ,ETIOLOGY of diseases ,EXOCRINE glands ,MONOCYTES ,CHEMOKINES ,DISEASES - Abstract
Objective. To investigate how monocyte chemotactic protein-1 (MCP-1) is involved in the pathological process of primary SS (pSS). [ABSTRACT FROM PUBLISHER]
- Published
- 2010
- Full Text
- View/download PDF
43. A single centre retrospective analysis of AECG classification criteria for primary Sjögren’s syndrome based on 112 minor salivary gland biopsies in a Japanese population.
- Author
-
Nakamura, Hideki, Kawakami, Atsushi, Iwamoto, Naoki, Okada, Akitomo, Yamasaki, Satoshi, Tamai, Mami, Ida, Hiroaki, Takagi, Yukinori, Hayashi, Tomayoshi, Aoyagi, Kiyoshi, Nakamura, Takashi, and Eguchi, Katsumi
- Subjects
- *
SJOGREN'S syndrome , *TECHNICAL specifications , *SALIVARY gland diseases , *BIOPSY , *RHEUMATOLOGY - Abstract
Objective. To assess the usefulness and performance of the American European Consensus Group (AECG) criteria based on minor salivary gland biopsy (MSGB) in Japanese patients with primary SS. [ABSTRACT FROM PUBLISHER]
- Published
- 2010
- Full Text
- View/download PDF
44. Cutaneous vasculitis induced by TNF inhibitors: a report of three cases.
- Author
-
Fujikawa, Keita, Kawakami, Atsushi, Hayashi, Tomayoshi, Iwamoto, Naoki, Kawashiri, Shin-ya, Aramaki, Toshiyuki, Ichinose, Kunihiro, Tamai, Mami, Arima, Kazuhiko, Kamachi, Makoto, Yamasaki, Satoshi, Nakamura, Hideki, Ida, Hiroaki, Origuchi, Tomoki, and Eguchi, Katsumi
- Subjects
CASE studies ,VASCULITIS ,TUMOR necrosis factors ,INFLIXIMAB ,ETANERCEPT - Abstract
We describe 3 rheumatoid arthritis (RA) patients with anti-tumor necrosis factor (TNF) therapy-induced cutaneous vasculitis. Two cases were induced by infliximab and the other, in whom cutaneous vasculitis was found early at the start of therapy, was induced by etanercept. Skin biopsy was obtained in 2 patients, with histology-proven leukocytoclastic vasculitis. One patient spontaneously improved after cessation of the TNF inhibitor. Two patients required oral corticosteroid, the efficacy of which was observed to be excellent and rapid. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
45. Switching to the anti-interleukin-6 receptor antibody tocilizumab in rheumatoid arthritis patients refractory to antitumor necrosis factor biologics.
- Author
-
Kawashiri, Shin-ya, Kawakami, Atsushi, Iwamoto, Naoki, Fujikawa, Keita, Aramaki, Toshiyuki, Tamai, Mami, Arima, Kazuhiko, Ichinose, Kunihiro, Kamachi, Makoto, Yamasaki, Satoshi, Nakamura, Hideki, Origuchi, Tomoki, Ida, Hiroaki, and Eguchi, Katsumi
- Subjects
INTERLEUKIN-6 ,IMMUNOGLOBULINS ,RHEUMATOID arthritis ,ANTINEOPLASTIC agents ,TUMOR necrosis factors ,PATIENTS - Abstract
We evaluated the short-term effects of the anti-interleukin-6 (IL-6) receptor antibody tocilizumab (TCZ) in six patients with rheumatoid arthritis (RA) who had been refractory to tumor necrosis factor (TNF) antagonist therapy. All subjects were considered to be secondary nonresponders to TNF antagonists as decided by each physician. The Disease Activity Score of 28 Joints (DAS28) appeared to improve slowly by TCZ compared with TNF antagonist therapy, but significantly decreased at 24 weeks. One patient achieved DAS28 remission [DAS28–erythrocyte sedimentation rate (ESR) <2.60, and 5 of 6 patients showed good or moderate clinical response. The change in the clinical Disease Activity Index was similar to that of the DAS28–ESR. The serum level of matrix metalloproteinase-3 (MMP-3), a marker for synovial overgrowth, also significantly decreased after the treatment (518 ± 567 at baseline, 141 ± 90 ng/ml at 24 weeks, p < 0.05). One patient discontinued TCZ because of tuberculous peritonitis. Although physicians need to watch for infectious adverse events, these data indicate that TCZ is effective for treating RA patients refractory to TNF antagonists. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
46. Prediction of DAS28-CRP remission in patients with rheumatoid arthritis treated with tacrolimus at 6 months by baseline variables.
- Author
-
Aramaki, Toshiyuki, Kawakami, Atsushi, Iwamoto, Naoki, Fujikawa, Keita, Kawashiri, Shin-ya, Tamai, Mami, Arima, Kazuhiko, Kamachi, Makoto, Yamasaki, Satoshi, Nakamura, Hideki, Nakashima, Munetoshi, Mizokami, Akinari, Furuyama, Masako, Matsuoka, Naoki, Ueki, Yukitaka, Ida, Hiroaki, Origuchi, Tomoki, Aoyagi, Kiyoshi, and Eguchi, Katsumi
- Subjects
DISEASE remission ,TACROLIMUS ,RHEUMATOID arthritis ,C-reactive protein ,AUTOIMMUNE diseases ,IMMUNOSUPPRESSIVE agents - Abstract
We attempted to determine what baseline variables are responsible for the efficacy of tacrolimus at 6 months in Japanese patients with rheumatoid arthritis (RA). One hundred and six RA patients treated with tacrolimus for 6 months were entered in this study. The outcome was set as the achievement of Disease Activity Score 28 C-reactive protein (DAS28-CRP) remission at 6 months. We examined the association of gender, DAS28-CRP at baseline, concomitant use of methotrexate (MTX), and concomitant use of prednisolone with the achievement of DAS28-CRP remission at 6 months by logistic regression analysis. Twenty-three of 106 patients (21.7%) achieved DAS28-CRP remission at 6 months. There was concomitant use of MTX by 20 patients (18.9%), prednisolone by 93 (87.7%), and prednisolone >5 mg/day by 43 (40.6%) at baseline. Logistic regression analysis showed that male gender (first) and moderate disease activity at baseline (second) are independent predictors toward achieving DAS28-CRP remission at 6 months. Maximum tacrolimus dosage administrated for patients over a 6-month period appeared not to be predictive for the DAS28-CRP remission at 6 months. In conclusion, we revealed for the first time that good outcome in RA patients treated with tacrolimus can be predictive by some baseline variables. That is clinically valuable for daily practice in the choice of disease-modifying antirheumatic drugs (DMARDs), especially tacrolimus. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
47. Prediction of DAS28-ESR remission at 6 months by baseline variables in patients with rheumatoid arthritis treated with etanercept in Japanese population.
- Author
-
Iwamoto, Naoki, Kawakami, Atsushi, Fujikawa, Keita, Aramaki, Toshiyuki, Kawashiri, Shin-ya, Tamai, Mami, Arima, Kazuhiko, Ichinose, Kunihiro, Kamachi, Makoto, Yamasaki, Satoshi, Nakamura, Hideki, Nakashima, Munetoshi, Mizokami, Akinari, Goto, Akiko, Fukuda, Takaaki, Matsuoka, Naoki, Ueki, Yukitaka, Tsukada, Toshiaki, Migita, Kiyoshi, and Shoumura, Fumiko
- Subjects
ETANERCEPT ,RHEUMATOID arthritis ,METHOTREXATE ,DISEASE remission ,EPIDEMIOLOGY - Abstract
We tried to determine which baseline variables are responsible for remission induction at 6 months in unselected rheumatoid arthritis (RA) patients of Japanese population treated with etanercept. One hundred forty-one patients with RA who were administered etanercept were registered. Thirty-four patients were started on etanercept monotherapy, 60 patients on cotherapy with methotrexate (MTX) (MTX cotherapy), and 47 patients on cotherapy with other non-MTX nonbiologic disease-modifying antirheumatic drugs (DMARDs) (non-MTX cotherapy). None of the patients were treated with both MTX and non-MTX nonbiologic DMARDs at entry. Outcome was set as achievement of disease activity score 28 (DAS28)-ESR remission at 6 months. We examined association of gender, DAS at baseline, MTX cotherapy at baseline, non-MTX cotherapy at baseline, and prednisolone use at baseline with achievement of remission at 6 months by logistic regression analysis. All subjects were classified as having high ( N = 109) or moderate disease activity ( N = 32) at entry. One hundred twenty out of 141 patients (85.1%) continued treatment with etanercept at 6 months. Continuation rate was statistically higher in MTX cotherapy (93.3%) compared with etanercept monotherapy (73.5%), and tended to be higher than with non-MTX cotherapy (85.1%). Logistic regression analysis identified that MTX cotherapy at entry and moderate disease activity at entry were independent variables for remission induction at 6 months. Accordingly, DAS28-ESR at 6 months was significantly lower with MTX cotherapy as compared with etanercept monotherapy or non-MTX cotherapy. To a lesser extent, DAS28-ESR with non-MTX cotherapy at 6 months was lower than with etanercept monotherapy. In this study of unselected patients, use of MTX and moderate disease activity at entry were associated with higher likelihood of response to etanercept. Non-MTX nonbiologic DMARDs may be an alternative in RA patients administrated etanercept who are intolerant to MTX. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
48. A case of cold agglutinin disease in the course of treatment for polymyalgia rheumatica.
- Author
-
Nakamura, Hideki, Kamiya-Matsumoto, Kayo, Kawakami, Atsushi, Ida, Hiroaki, Hayashi, Tomayoshi, Sato, Shinichi, Kamihira, Shimeru, and Eguchi, Katsumi
- Subjects
- *
POLYMYALGIA rheumatica , *RAYNAUD'S disease , *COMMON cold , *ANEMIA , *COLD agglutinin syndrome - Abstract
A 60-year-old male who had been treated for polymyalgia rheumatica (PMR) with Raynaud’s phenomenon was admitted to our hospital with acrocyanosis and rapid progressive anemia. Hemolytic anemia with reduction of haptoglobin and cold agglutinin was detected, and the patient had a negative Donath-Landsteiner test. A skin biopsy from his toe revealed microthromboembolism without vasculitis, resulting in the diagnosis of cold agglutinin disease (CAD). This is a first case report of CAD complicated with PMR. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
49. A significantly impaired natural killer cell activity due to a low activity on a per-cell basis in rheumatoid arthritis.
- Author
-
Aramaki, Toshiyuki, Ida, Hiroaki, Izumi, Yasumori, Fujikawa, Keita, Huang, Mingguo, Arima, Kazuhiko, Tamai, Mami, Kamachi, Makoto, Nakamura, Hideki, Kawakami, Atsushi, Origuchi, Tomoki, Matsuoka, Naoki, and Eguchi, Katsumi
- Subjects
KILLER cells ,RHEUMATOID arthritis ,CELL receptors ,MOLECULES ,SJOGREN'S syndrome ,PATIENTS - Abstract
To elucidate the characterization of peripheral natural killer (NK) cells in patients with rheumatoid arthritis (RA), we investigated the NK cell activity, the expression of NK cell activating receptors and intracellular molecules. The NK activity was analyzed in 27 RA patients, 22 primary Sjögren’s syndrome (SS) patients, and 15 healthy individuals using the
51 Chrominium release assay. The expression of NK cell activating receptors (NKG2D, CD244, CD2, and CD16) and intracellular molecules (granzyme B, perforin, and TCR ζ chain) in CD3-CD56+ cells were characterized by flow cytometry. The serum cytokine levels (IL-6, TNFα, and IL-18) were measured using ELISA. Both the NK cell activity and the activity on a per-cell basis were observed to significantly decrease in the RA patients in comparison to the controls. The expression of NKG2D and CD244 also significantly decreased in both the RA and primary SS patients, whereas the significant decrease in the CD16 expression was only observed in the RA patients. The titer of the serum IL-6, TNFα, and IL-18 was significantly higher in the RA patients than in the controls. These data suggest that a low NK activity on a per-cell basis might therefore contribute to an impaired NK activity in the patients with RA. [ABSTRACT FROM AUTHOR]- Published
- 2009
- Full Text
- View/download PDF
50. CTACK/CCL27 Accelerates Skin Regeneration via Accumulation of Bone Marrow-Derived Keratinocytes.
- Author
-
Inokuma, Daisuke, Abe, Riichiro, Fujita, Yasuyuki, Sasaki, Mikako, Shibaki, Akihiko, Nakamura, Hideki, McMillan, James R., Shimizu, Tadamichi, and Shimizu, Hiroshi
- Subjects
BONE marrow cells ,B cells ,STEM cells ,KERATINOCYTES ,WOUND healing ,T cells ,CHEMOKINES - Abstract
Recent studies have suggested that bone marrow (BM) cells transdifferentiate to regenerate a variety of cellular lineages. Due to the relatively small population of BM-derived cells in each organ, it is still controversial whether these BM-derived cells are really present in sufficient numbers for effective function. Conversely, it is speculated that chemokine/chemokine receptor interactions mediate this migration of the tissue-specific precursor cells from BM into the target tissue. Here, we show that cutaneous T-cell attracting chemokine (CTACK)/CCL27 is the major regulator involved in the migration of keratinocyte precursor cells from BM into skin. By screening various chemokine expression patterns, we demonstrated that CTACK is constitutively expressed in normal skin and upregulated in wounds and that approximately 20% of CD34
+ BM cells expressed CCR10, the ligand for CTACK. Intradermal injection of CTACK/CCL27 into the periphery of skin wounds significantly enhanced BM-derived keratinocyte (BMDK) migration, and CTACK/CCL27 neutralizing antibody inhibited this BMDK migration. Furthermore, increased BMDK migration caused by CTACK/CCL27 significantly accelerated the wound-healing process without any influence over either angiogenesis or keratinocyte proliferation. These results provide direct evidence that recruitment of BM keratinocyte precursor cells to the skin is regulated by specific chemokine/chemokine receptor interactions, making possible the development of new regenerative therapeutic strategies. [ABSTRACT FROM AUTHOR]- Published
- 2006
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.